Swiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems

First Multi-System Agreement by a Hospital for Both Accuray and RaySearch Products The Swiss Medical Network, Accuray and RaySearch Have Also Partnered to Expand Opportunities for Training Healthcare Professionals on the Latest Technologies SUNNYVALE... Devices, Oncology Accuray, RaySearch, Radixact, CyberKnife, RayStation, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractPurpose of ReviewFollowing partial mastectomy, whole-breast irradiation (WBI), delivered over 3 to 6  weeks, has been the standard adjuvant radiation approach for early-stage breast cancer. A growing body of literature over the past decade has suggested that irradiation of the partial breast, including the tumor bed plus a margin, may be a suitable alternative for appropriately selected patients. The use of partial breast irradiation (PBI) has been studied in multiple prospective randomized trials, now with up to 10 years of follow-up, establishing similar safety and efficacy compared with WBI. Advantages...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
Breast conserving surgery (BCS) followed by radiation therapy (RT) is the primary management for many women with early-stage, invasive breast cancer and ductal carcinoma in situ (DCIS) [1 –4]. Most women achieve good to excellent cosmesis after BCS and RT but some experience cosmetic failure, defined as fair or poor cosmetic outcomes [5–17]. However, comparisons of cosmetic outcomes across international jurisdictions using contemporary surgical and RT techniques for DCIS are lack ing.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Proton therapy has an important role in the management of head and neck cancer, where the dosimetric characteristics of proton particles are advantageous for treating tumors in complex anatomic areas. In addition to highly targeted dose depositions owing to the Bragg peak and superior lateral dose distribution of proton therapy, the introduction of spot-scanning techniques that allow intensity-modulated proton therapy (IMPT) further improve dose distributions and normal-tissue sparing relative to intensity-modulated (photon) radiation therapy (IMRT), a finding that has been validated in case-matched analyses showing lower ...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
The radiobiological principles of stereotactic body radiation therapy (SBRT) are currently vividly discussed [1 –3]. Compared to conventional fractionation, SBRT may exhibit some unique biological features including beneficial effects such as enhancement of systemic anti-tumor immunity [4] and a better ability to kill cancer stem cells [5], but also a difficulty to overcome tumor hypoxia with one or only a few fractions due to limited reoxygenation [2,3]. More specifically, when cells in vitro are irradiated with doses comparably high to those used in SBRT, a deviation from the typical linear-quadratic shape of the c...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Radiation therapy is one of the main pillars of cancer treatment. As precision medicine is adopted more widely, individualization of radiation therapy based on patients ’ biological information is becoming more important [1]. However, the biological profiles associated with cancer cell radiosensitivity have not yet been fully elucidated [1]. Clonogenic assays are the gold standard for determining reproductive cell death induced by ionizing radiation [2]. Past stu dies have shown that ex vivo SF2 (clonogenic survival after 2 Gy irradiation) is relevant to the tumor response to radiation therapy [3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
The identification and accurate contouring of the intraprostatic tumor volume is a crucial step for diagnostic and therapeutic approaches in patients with primary prostate cancer (PCa). In the last decade the concept of focal radiation therapy (RT) has gained interest for patients with PCa and boosting the RT dose to the visible tumor areas within the prostate may improve treatment outcome [1,2]. Moreover, recurrent PCa after conventional RT often occurs at the site of the primary tumor [3,4]. Currently, several phase III trials (e.g.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Hepatocellular carcinoma (HCC) is one of the quickest growing causes of cancer death in the northern hemisphere. Transplant and resection, the only treatments considered curative, are feasible in only a small minority of patients. Consequently, the landscape of HCC treatment has greatly expanded over the past 10 years. Patients are undergoing treatment with a wide variety of nonoperative interventions, including transarterial chemoembolization and radioembolization using Yttrium-90, and an expanding array of systemic treatments, including sorafenib, regorafenib, and nivolumab.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
We read with interest the article published by Palma et  al reporting a phase 2 clinical trial of preoperative stereotactic ablative radiation therapy (SABR) plus surgery in patients with early stage non-small cell lung cancer (NSCLC).1 Surgery was implemented in 10 weeks after SABR. The authors concluded that the pathologic complete response (pCR) rate after SABR was 60%, which was lower than the hypothesized 90% pCR rate. Preoperative SABR and surgery combination did not increase toxicity more than surgery alone, and there was no perioperative mortality.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
Cancer of the true glottis has a very low rate of regional metastasis; thus, curative treatment depends on optimized local therapy, with disease-free survival rates in excess of 90%.1 For radiation therapy, the challenge has been enhancing efficacy while preserving or improving the late toxicity of treatment, including effects on voice quality and laryngeal function. As context, hypofractionated radiation therapy (2.25 Gy daily) has been shown to improve local control for early stage glottic cancer compared with daily 2 Gy regimens, with acceptable toxicity of ∼15% to 20% late grade 1 skin or laryngeal effects.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
External beam radiation therapy (RT) is currently a standard of care for early stage (T1-T2) glottic cancer, but it is being gradually supplanted by surgical approaches; endoscopic, laser, and robotic techniques allow less invasive access to glottic tumors, despite some evidence of worse oncologic outcomes.1 Surgical excision is often chosen, likely because of the increased convenience of a single outpatient procedure compared with several weeks of daily radiation treatments and the benefit of avoiding substantial radiation exposure to the normal tissues surrounding the larynx with standard 2-dimensional techniques, which ...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | Pharmaceuticals | Radiation Therapy | Switzerland Health | Training | Universities & Medical Training